New technologies of hypotensive drug delivery in glaucoma treatment
https://doi.org/10.21516/2072-0076-2018-11-4-103-107
Abstract
The paper reports on promising methods of drug delivery in glaucoma treatment: contact lenses, punctum plugs, intraocular implants, subconjunctival and supraciliary injections, ocular rings, hydrogels, nanocarriers.
About the Authors
O. A. Kiseleva
Moscow Helmholtz Research Institute of Eye Diseases
Russian Federation
Russian Federation
Dr. Med. Sci., head of the glaucoma department
14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062, Russia
A. M. Bessmertny
Moscow Helmholtz Research Institute of Eye Diseases
Russian Federation
Russian Federation
Dr. Med. Sci., senior researcher, glaucoma department
14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062, Russia
L. V. Yakubova
Moscow Helmholtz Research Institute of Eye Diseases
Russian Federation
Russian Federation
Cand. Med. Sci., senior researcher, glaucoma department
14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062, Russia
References
1. Ciolino J.B., Ross A.E., Tulsan R., et al. Latanoprost-eluting contact lenses in glaucomatous monkeys. Ophthalmology. 2016; 123 (10): 2085–92. doi: 10.1016/j.ophtha.2016.06.038
2. Peng C.C., Ben-Shlomo A., Mackay E.O., et al. Drug delivery by contact lens in spontaneously glaucomatous dogs. Curr. Eye Res. 2012; 37 (3): 204–11. doi: 10.3109/02713683
3. Ocular Therapeutix is currently enrolling patients in a phase 3 trial with OTX-TP. Available at: https://www.ocutx.com/research/otx-tp/
4. Perera S.A., Ting D.S., Nongpiur M.E., et al. Feasibility study of sustainedrelease travoprost punctum plug for intraocular pressure reduction in an Asian population. Clin. Ophthalmol. 2016; 10: 757–64. doi:10.2147/OPTH.S102181
5. Mati Therapeutics Inc. Announces Initiation of Phase II Study. Available at: http://www.matitherapeutics.com/about/press/compare-latanoprostto-timolol
6. Lewis R.A., Christie W.C., Day D.G., et al. Bimatoprost sustained-release implants for glaucoma therapy: 6-month results from a phase I/II clinical trial. Am. J. Ophthalmol. 2017; 175 (3): 137–47. doi: 10.1016/j.ajo.2016.11.020
7. Fu J., Sun F., Liu W., et al. Subconjunctival delivery of dorzolamide-loaded poly(ether-anhydride) microparticles produces sustained lowering of intraocular pressure in rabbits. Mol. Pharm. 2016; 13 (9): 2987–95. doi: 10.1021/acs.molpharmaceut.6b00343
8. Kopp F., Eickner T., Polei S., et al. Ultrahigh field MR imaging of a subconjunctival anti-glaucoma drug delivery system in a rabbit model. Sci. Rep. 2017; 7 (1): 15780. Available at: https://www.nature.com/articles/s41598-017-15954-w
9. Lavik E., Kuehn M.H., Shoffstall A.J., et al. Sustained delivery of timolol maleate for over 90 days by subconjunctival injection. J. Ocul. Pharmacol. Ther. 2016; 32 (10): 642–9. doi: 10.1089/jop.2016.0042
10. Wong T.T., Novack G.D., Natarajan J.V., et al. Nanomedicine for glaucoma: sustained release latanoprost offers a new therapeutic option with substantial benefits over eyedrops. Drug Deliv. Transl. Res. 2014; 4 (4): 303–9. doi: 10.1007/s13346-014-0196-9
11. Kim Y.C., Edehauser H.F., Prausnitz M.R. Targeted delivery of anti-glaucoma drugs to the supraciliary space using microneedles. Invest. Ophthalmol. Vis. Sci. 2014; 55 (11): 7387–97. doi: 10.1167/iovs.14-14651
12. Chiang B., Kim Y.C., Doty A.C., et al. Sustained reduction of intraocular pressure by supraciliary delivery of brimonidine-loaded poly(lactic acid) microspheres for the treatment of glaucoma. J. Control Release 2016; 228: 48–57. doi: 10.1016/j.jconrel.2016.02.041
13. Stewart R.H., Novak S. Introduction of the OCUSERT ocular system to an ophthalmic practice. Ann. Ophthalmol. 1978; 10 (3): 325–30.
14. Brandt J.D., Sall K., DuBiner H., et al. Six-month intraocular pressure reduction with a topical bimatoprost ocular insert. Results of a Phase II randomized controlled study. Ophthalmology. 2016; 123 (8): 1685–94. doi: 10.1016/j.ophtha.2016.04.026
15. Dubey A., Prabhu P. Formulation and evaluation of stimuli-sensitive hydrogels of timolol maleate and brimonidine tartrate for the treatment of glaucoma. Int. J. Pharm. Invest. 2014; 4 (3): 112–8. doi: 10.4103/2230-973X.138340
16. Fedorchak M.V., Conner I.P., Schuman J.S., et al. Long-term glaucoma drug delivery using a topically retained gel/microsphere eye drop. Sci. Rep. 2017; 7 (1): 8639. doi: 10.1038/s41598-017-09379-8
17. Wadhwa S., Paliwal R., Paliwal S.R., Vyas S.P. Hyaluronic acid modified chitosan nanoparticles for effective management of glaucoma: development, characterization, and evaluation. J. Drug Target. 2010; 18 (4): 292–302. doi: 10.3109/10611860903450023
18. Fulgencio Gde. O., Viana F.A., Ribeiro R.R., et al. New mucoadhesive chitosan film for ophthalmic drug delivery of timolol maleate: in vivo evaluation. J. Ocul. Pharmacol. Ther. 2012; 28 (4): 350–8. doi: 10.1089/jop.2011.0174
19. Ibrahim M.M., Abd-Elgawad A.H., Soliman O.A., Jablonski M.M. Natural bioadhesive biodegradable nanoparticle-based topical ophthalmic formulations for management of glaucoma. Transl. Vis. Sci. Technol. 2015; 4 (3): 12. doi: 10.1167/tvst.4.3.12
20. Cheng Y.H., Tsai T.H., Jhan Y.Y., et al. Thermosensitive chitosan-based hydrogel as a topical ocular drug delivery system of latanoprost for glaucoma treatment. Carbohydr. Polym. 2016; 144: 390–9. https://doi.org/10.1016/j.carbpol.2016.02.080
21. Gupta S., Vyas S.P. Carbopol/chitosan based pH triggered in situ gelling system for ocular delivery of timolol maleate. Sci. Pharm. 2010; 78: 959-76. doi: 10.3797/scipharm.1001-06
22. Li H., Liu Y., Zhang Y., et al. Liposomes as a novel ocular delivery system for brinzolamide: in vitro and in vivo studies. AAPS Pharm. Sci. Tech. 2016; 17 (3): 710–7. doi:10.1208/s12249-015-0382-1
23. Huang Y., Tao Q., Hou D. A novel ion-exchange carrier based upon liposomeencapsulated montmorillonite for ophthalmic delivery of betaxolol hydrochloride. Int. J. Nanomedicine. 2017; 12: 1731–45. doi: 10.2147/IJN.S122747
24. Natarajan J.V., Ang M., Darwitan A., et al. Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye. Int. J. Nanomedicine. 2012; 7: 123–31. doi: 10.2147/IJN.S25468
25. Mokhtar Ibrahim M., Tawfique S.A., Mahdy M.M. Liposomal diltiazem HCl as ocular drug delivery system for glaucoma. Drug Dev. Ind. Pharm. 2014; 40 (6): 765–73. doi: 10.3109/03639045.2013.783589
26. Kouchak M., Malekahmadi M., Bavarsad N., et al. Dorzolamide nanoliposome as a long action ophthalmic delivery system in open angle glaucoma and ocular hypertension patients. Drug Dev. Ind. Pharm. 2018; 44 (8): 1239–42. doi: 10.1080/03639045.2017.1386196
27. Hasan A.A. Design and in vitro characterization of small unilamellar niosomes as ophthalmic carrier of dorzolamide hydrochloride. Pharm. Dev. Technol. 2014; 19 (6): 748–75. doi: 10.3109/10837450.2013.829095
28. Hashemi Dehaghi M., Haeri A., Keshvari H. Dorzolamide loaded niosomal vesicles: comparison of passive and remote loading methods. Iran J. Pharm. Res. 2017; 16 (2): 413–22. https://www.ncbi.nlm.nih.gov/pubmed/28979296
29. Huang J., Peng T., Li Y., et al. Ocular cubosome drug delivery system for timolol maleate: preparation, characterization, cytotoxicity, ex vivo, and in vivo evaluation. AAPS Pharm. Sci. Tech. 2017; 18 (8): 2919–26. doi: 10.1208/s12249-017-0763-8
30. Li C.C., Abrahamson M., Kapoor Y., Chauhan A. Timolol transport from microemulsions trapped in HEMA gels. J. Colloid Interface Sci. 2007; 315 (1): 297–306. doi:10.1016/j.jcis.2007.06.054
31. Morsi N., Ibrahim M., Refai H., El Sorogy H. Nanoemulsion-based electrolyte triggered in situ gel for ocular delivery of acetazolamide. Eur. J. Pharm. Sci. 2017; 104: 302–14. doi: 10.1016/j.ejps.2017.04.013
32. Lallemand F., Daull P., Benita S., et al. Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb. J. Drug Deliv. 2012; 2012: 604204. doi: 10.1155/2012/604204
33. Ammar H.O., Salama H.A., Ghorab M., Mahmoud A.A. Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride. AAPS Pharm. Sci. Tech. 2009; 10 (3): 808–19. doi: 10.1208/s12249-009-9268-4
34. Shokry M., Hathout R.M., Mansour S. Exploring gelatin nanoparticles as novel nanocarriers for timolol maleate: Augmented in-vivo efficacy and safe histological profile. Int. J. Pharm. 2018; 545 (1–2): 229–39. doi: 10.1016/j.ijpharm.2018.04.059
35. El-Salamouni N.S., Farid R.M., El-Kamel A.H., El-Gamal S.S. Nanostructured lipid carriers for intraocular brimonidine localisation: development, in vitro and in vivo evaluation. J. Microencapsul. 2018; 35 (1): 102–13. doi: 10.1080/02652048.2018.1425753
36. Ilka R., Mohseni M., Kianirad M., et al. Nanogel-based natural polymers as smart carriers for the controlled delivery of timolol maleate through the cornea for glaucoma. Int. J. Biol. Macromol. 2018; 109: 955–62. doi: 10.1016/j.ijbiomac.2017.11.090
37. Ikuta Y., Aoyagi S., Tanaka Y. Creation of nano eye-drops and effective drug delivery to the interior of the eye. Sci. Rep. 2017; 7: 44229. doi: 10.1038/srep44229
38. Park C.G., Kim Y.K., Kim S.N., et al. Enhanced ocular efficacy of topicallydelivered dorzolamide with nanostructured mucoadhesive microparticles. Int. J. Pharm. 2017; 522 (1–2): 66–73. doi: 10.1016/j.ijpharm.2017.02.035
39. Afify EAMR., Elsayed I., Gad M.K., et al. Enhancement of pharmacokinetic and pharmacological behavior of ocular dorzolamide after factorial optimization of self-assembled nanostructures. PLoS One. 2018; 13 (2): e0191415. doi: 10.1371/journal.pone.0191415
40. Lambert W.S., Carlson B.J., van der Ende A.E., et al. Nanosponge-mediated drug delivery lowers intraocular pressure. Transl. Vis. Sci. Technol. 2015; 4 (1): 1. doi:10.1167/tvst.4.1.1
41. Chan H.H., Wong T.T., Lamoureux E., et al. A survey on the preference of sustained glaucoma drug delivery systems by Singaporean Chinese patients: a comparison between subconjunctival, intracameral, and punctal plug routes. J. Glaucoma. 2015; 24 (7): 485–92. doi: 10.1097/IJG.0000000000000197
42. Varadaraj V., Kahook M.Y., Ramulu P.Y., Pitha I.F. Patient acceptance of sustained glaucoma treatment strategies. J. Glaucoma. 2018; 27 (4): 328–35. doi: 10.1097/IJG.0000000000000913
43. Ozdemir S., Wong T.T., Allingham R.R., Finkelstein E.A. Predicted patient demand for a new delivery system for glaucoma medicine. Medicine (Baltimore). 2017; 96 (15): e6626. doi: 10.1097/MD.0000000000006626
Review
For citations:
Kiseleva O.A., Bessmertny A.M., Yakubova L.V. New technologies of hypotensive drug delivery in glaucoma treatment. Russian Ophthalmological Journal. 2018;11(4):103-107. (In Russ.) https://doi.org/10.21516/2072-0076-2018-11-4-103-107
Views:
1034
Email this article 